• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺泡表面活性物质相关蛋白A、磷脂酰胆碱及肺泡表面活性物质抑制剂在上皮衬液中的情况。与表面活性、呼吸窘迫综合征严重程度及小早产儿预后的相关性

Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants.

作者信息

Hallman M, Merritt T A, Akino T, Bry K

机构信息

Department of Pediatrics, University of Helsinki, Finland.

出版信息

Am Rev Respir Dis. 1991 Dec;144(6):1376-84. doi: 10.1164/ajrccm/144.6.1376.

DOI:10.1164/ajrccm/144.6.1376
PMID:1741552
Abstract

Although surfactant deficiency at birth is the major cause of respiratory distress syndrome (RDS), there is insufficient data on surfactant and surfactant inhibitors after birth. In the present study, a total of 345 airway specimens (AS) from 61 neonates of gestational age of 24 to 29 wk (54 with RDS) were analyzed for concentrations of phosphatidylcholine (PC), saturated PC (SPC), surfactant protein A (SP-A), nonsedimentable protein, and free amino acids in epithelial lining fluid (ELF). The relationship between surfactant indices, surface activity, and severity of RDS was studied. Treatment with human surfactant containing SP-A increased [PC]ELF and [SPC]ELF to levels found in infants without RDS. In placebo-treated infants similar concentrations were first reached between Days 4 and 7. Surfactant treatment increased the low SP-A/SPC ratio, although this ratio remained lower than that in exogenous surfactant. In RDS, the concentrations of free amino acids in ELF were 6 to 31 times higher than in infants without RDS. The nonsedimentable proteins of AS and cationic amino acids increased the minimum surface tension of SP-A-deficient surfactant from AS. Addition of SP-A improved the surface activity. According to multiple regression analysis, In [PC]ELF (p less than 0.0001), SPC/PC ratio (p less than 0.0001), In SP-A/SPC ratio (p less than 0.0002), and [protein]ELF (p less than 0.01) correlated with alveolar-arterial oxygen pressure gradient. Of the infants weighing less than 1,000 g, those who were going to die or develop bronchopulmonary dysplasia had a strikingly lower SP-A/SPC ratio during the first week (less than 25 ng/nmol) than those surviving without BPD.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

尽管出生时表面活性剂缺乏是呼吸窘迫综合征(RDS)的主要原因,但关于出生后表面活性剂和表面活性剂抑制剂的数据不足。在本研究中,对61例孕龄24至29周的新生儿(54例患有RDS)的345份气道标本(AS)进行了分析,以测定上皮衬液(ELF)中磷脂酰胆碱(PC)、饱和PC(SPC)、表面活性蛋白A(SP-A)、不可沉降蛋白和游离氨基酸的浓度。研究了表面活性剂指标、表面活性与RDS严重程度之间的关系。含SP-A的人表面活性剂治疗使[PC]ELF和[SPC]ELF升高至无RDS婴儿的水平。在安慰剂治疗的婴儿中,相似浓度在第4天至第7天首次达到。表面活性剂治疗增加了低SP-A/SPC比值,尽管该比值仍低于外源性表面活性剂中的比值。在RDS中,ELF中游离氨基酸的浓度比无RDS的婴儿高6至31倍。AS的不可沉降蛋白和阳离子氨基酸增加了AS中SP-A缺乏的表面活性剂的最小表面张力。添加SP-A可改善表面活性。根据多元回归分析,ln[PC]ELF(p<0.0001)、SPC/PC比值(p<0.0001)、ln SP-A/SPC比值(p<0.0002)和[蛋白]ELF(p<0.01)与肺泡-动脉氧分压梯度相关。体重小于1000 g的婴儿中,那些将死亡或发生支气管肺发育不良的婴儿在第一周的SP-A/SPC比值(低于25 ng/nmol)明显低于无支气管肺发育不良存活的婴儿。(摘要截短于250字)

相似文献

1
Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants.肺泡表面活性物质相关蛋白A、磷脂酰胆碱及肺泡表面活性物质抑制剂在上皮衬液中的情况。与表面活性、呼吸窘迫综合征严重程度及小早产儿预后的相关性
Am Rev Respir Dis. 1991 Dec;144(6):1376-84. doi: 10.1164/ajrccm/144.6.1376.
2
Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome.呼吸窘迫综合征中的表面活性物质蛋白A和饱和磷脂酰胆碱
Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1672-7. doi: 10.1164/ajrccm.150.6.7952631.
3
Prenatal dexamethasone and exogenous surfactant therapy: surface activity and surfactant components in airway specimens.产前地塞米松与外源性表面活性剂治疗:气道标本中的表面活性及表面活性剂成分
Pediatr Res. 1995 Nov;38(5):676-84. doi: 10.1203/00006450-199511000-00008.
4
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome.一项关于卢西纳可坦与猪肺磷脂在极早早产儿呼吸窘迫综合征高危人群中进行的多中心、随机、对照试验。
Pediatrics. 2005 Apr;115(4):1030-8. doi: 10.1542/peds.2004-2231.
5
A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants.一项关于卢西纳可、棕榈酰可福斯汀和贝拉克坦预防极早产儿呼吸窘迫综合征的多中心、随机、盲法对照试验。
Pediatrics. 2005 Apr;115(4):1018-29. doi: 10.1542/peds.2004-2183.
6
Compare severity of bronchopulmonary dysplasia in neonates with respiratory distress syndrome treated with surfactant to without surfactant.比较接受表面活性剂治疗和未接受表面活性剂治疗的新生儿呼吸窘迫综合征患者支气管肺发育不良的严重程度。
J Med Assoc Thai. 2011 Aug;94 Suppl 3:S35-40.
7
Ontogeny of surfactant proteins A and B in human amniotic fluid as indices of fetal lung maturity.人羊水表面活性物质蛋白A和B的个体发生作为胎儿肺成熟度的指标
Pediatr Res. 1991 Dec;30(6):597-605. doi: 10.1203/00006450-199112000-00023.
8
Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants.表面活性蛋白A基因多态性与早产儿支气管肺发育不良的风险
Turk J Pediatr. 2000 Jul-Sep;42(3):181-5.
9
Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure.表面活性剂替代对呼吸窘迫综合征肺流出物磷脂的影响:表面活性剂磷脂周转、储备量评估及其与呼吸衰竭严重程度的关系。
Pediatr Res. 1986 Dec;20(12):1228-35. doi: 10.1203/00006450-198612000-00008.
10
Pulmonary surfactant metabolism in infants lacking surfactant protein B.缺乏表面活性物质蛋白B的婴儿的肺表面活性物质代谢
Am J Respir Cell Mol Biol. 2000 Mar;22(3):380-91. doi: 10.1165/ajrcmb.22.3.3645.

引用本文的文献

1
The Therapeutic Potential of Myo-Inositol in Managing Patients with Respiratory Diseases.肌醇在呼吸系统疾病患者管理中的治疗潜力。
Int J Mol Sci. 2025 Feb 28;26(5):2185. doi: 10.3390/ijms26052185.
2
Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model.新型干粉式人工合成肺表面活性剂产品治疗新生儿呼吸窘迫综合征(RDS)的研发 - 第二部分:在兔肺表面活性剂洗脱模型中的体内药效学测试。
Pharm Res. 2024 Sep;41(9):1827-1842. doi: 10.1007/s11095-024-03754-7. Epub 2024 Sep 5.
3
How Does Airway Surface Liquid Composition Vary in Different Pulmonary Diseases, and How Can We Use This Knowledge to Model Microbial Infections?
气道表面液体成分在不同肺部疾病中如何变化,以及我们如何利用这些知识来模拟微生物感染?
Microorganisms. 2024 Apr 3;12(4):732. doi: 10.3390/microorganisms12040732.
4
Single nucleotide polymorphisms in surfactant protein A1 are not associated with a lack of responsiveness to antenatal steroid therapy in a pregnant sheep model.肺泡表面活性物质蛋白 A1 的单核苷酸多态性与产前类固醇治疗反应不良无关,在妊娠绵羊模型中。
Physiol Rep. 2022 Oct;10(19):e15477. doi: 10.14814/phy2.15477.
5
Management Practices During Perinatal Respiratory Transition of Very Premature Infants.极早产儿围产期呼吸过渡期间的管理实践
Front Pediatr. 2022 May 10;10:862038. doi: 10.3389/fped.2022.862038. eCollection 2022.
6
Surfactant Protein-A Function: Knowledge Gained From SP-A Knockout Mice.表面活性蛋白A的功能:从表面活性蛋白A基因敲除小鼠获得的知识
Front Pediatr. 2022 Jan 7;9:799693. doi: 10.3389/fped.2021.799693. eCollection 2021.
7
Differential Regulation of Human Surfactant Protein A Genes, SFTPA1 and SFTPA2, and Their Corresponding Variants.人表面活性蛋白 A 基因(SFTPA1 和 SFTPA2)及其变异体的差异调控。
Front Immunol. 2021 Nov 30;12:766719. doi: 10.3389/fimmu.2021.766719. eCollection 2021.
8
Sequential Exposure to Antenatal Microbial Triggers Attenuates Alveolar Growth and Pulmonary Vascular Development and Impacts Pulmonary Epithelial Stem/Progenitor Cells.产前连续接触微生物触发因素会减弱肺泡生长和肺血管发育,并影响肺上皮干细胞/祖细胞。
Front Med (Lausanne). 2021 Feb 22;8:614239. doi: 10.3389/fmed.2021.614239. eCollection 2021.
9
SP-A and SP-D: Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties.表面活性蛋白 A 和 D:具有抗病毒和免疫调节特性的双重功能免疫分子。
Front Immunol. 2021 Jan 19;11:622598. doi: 10.3389/fimmu.2020.622598. eCollection 2020.
10
Lack of whey acidic protein (WAP) four-disulfide core domain protease inhibitor 2 (WFDC2) causes neonatal death from respiratory failure in mice.缺乏乳清酸性蛋白 (WAP) 四硫键核心域蛋白酶抑制剂 2 (WFDC2) 导致小鼠因呼吸衰竭而在新生儿期死亡。
Dis Model Mech. 2019 Nov 12;12(11):dmm040139. doi: 10.1242/dmm.040139.